Cochrane Abstracts
Terazosin for benign prostatic hyperplasia
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Terazosin for Benign Prostatic Hyperplasia." Cochrane Abstracts, John Wiley & Sons, Inc, 2026. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/435721/all/Terazosin_for_benign_prostatic_hyperplasia.
Terazosin for benign prostatic hyperplasia. Cochrane Abstracts. John Wiley & Sons, Inc; 2026. https://evidence.unboundmedicine.com/evidence/view/Cochrane/435721/all/Terazosin_for_benign_prostatic_hyperplasia. Accessed January 12, 2026.
Terazosin for benign prostatic hyperplasia. (2026). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/435721/all/Terazosin_for_benign_prostatic_hyperplasia
Terazosin for Benign Prostatic Hyperplasia [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2026. [cited 2026 January 12]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/435721/all/Terazosin_for_benign_prostatic_hyperplasia.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Terazosin for benign prostatic hyperplasia
ID - 435721
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/435721/all/Terazosin_for_benign_prostatic_hyperplasia
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
